Close Menu
Business Voice NowBusiness Voice Now
    Facebook X (Twitter) Instagram
    Business Voice NowBusiness Voice Now
    Subscribe
    • Markets
      • IPO
      • Market News
    • Business
      • FMCG
      • Retail
      • Quick Commerce
      • Startups
    • Healthcare
    • Technology
    • Energy
    • Voices
      • Entrepreneur – CXO Stories
      • Corporate Office story
    • E Magazine
      • Year 2026
        • November 2026
        • October 2026
        • September 2026
        • August 2026
        • July 2026
    Business Voice NowBusiness Voice Now
    Home»Press Release»Troikaa Pharma Launches World’s First Zolpidem Sublingual Spray, Zolswift-SL, for Insomnia
    Press Release

    Troikaa Pharma Launches World’s First Zolpidem Sublingual Spray, Zolswift-SL, for Insomnia

    WebDeskBy WebDeskNovember 27, 2024No Comments2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Follow Us
    Google News Flipboard Threads
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Ahmedabad (Gujarat) [India], November 27: Troikaa Pharma announced that it has launched its Zolpidem Sublingual Spray 3.85% w/v, for the treatment of short term insomnia under the brand name of Zolswift-SL. Developed through extensive research & development, Zolswift-SL is the first ever sublingual Zolpidem spray in the world. The product has been approved by CDSCO (Central Drugs Standard Control Organisation). Zolswift-SL is protected by patents in India, US, Europe and over 100 countries.

    “Sleep disorder is a widely prevalent challenge people face due to stress and urban lifestyles, and Zolpidem oral tablets are commonly used in its treatment. Our clinical studies have indicated that Zolswift-SL Spray achieves faster therapeutic concentrations as compared to Zolpidem oral tablets, thereby leading to faster onset of action”, said Dr. Ketan R Patel, CMD of Troikaa Pharmaceuticals.

    Insomnia is a prevalent concern in India, affecting a significant part of the population. Prevalence of Insomnia in India has been estimated to be about 25.7% with higher prevalence amongst patients with diabetes and heart disease patients. The impact of sleep deprivation on health is deep and extensive. Our body requires optimum sleep for its repair and recovery. Sleep deprivation alters this repair function which may lead to changes in disease susceptibility and has been reported to be linked to many chronic health problems, including heart disease, kidney disease, high blood pressure, diabetes, stroke, obesity, and depression. Also, sleep disturbance is a risk factor for development of Alzheimer’s disease due to accumulation of amyloid-β (A β).

    Comparative clinical studies between Zolswift-SL Spray 3.85% w/v and Zolpidem Tartrate tablets clearly established that Zolswift-SL Spray achieves faster therapeutic concentrations in the blood as compared to Zolpidem oral tablets. The Pharmacodynamic assessment showed a quick onset of action with Zolswift-SL Sublingual spray in comparison to oral zolpidem tablets.

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    PR press-release
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    WebDesk
    • Website

    Related Posts

    Tutul Consulting: The CHRO’s Real Job Goes Beyond Keeping People Happy and More Toward Shaping Enterprise Mindset

    November 20, 2026

    Hardik Gajjar-led Medvyn Builds a National Platform for India’s Doctors, Hospitals and Healthcare Talent

    November 20, 2026

    How To Create a Home That Supports Both Rest and Productivity?

    November 20, 2026

    Comments are closed.

    Recent Post
    • IBMA Organises First-Ever Indian Lead Battery Conference 2026 in Goa
    • Why Creator-Gear is a B2B Business now: agencies, schools, and production houses?
    • Parul University moves to 401-500 band in Times Higher Education (THE) Interdisciplinary Science Rankings 2027
    • Tutul Consulting: The CHRO’s Real Job Goes Beyond Keeping People Happy and More Toward Shaping Enterprise Mindset
    • Hardik Gajjar-led Medvyn Builds a National Platform for India’s Doctors, Hospitals and Healthcare Talent
    • Mahanadi Coalfields becomes the third Coal India subsidiary to go public, will it continue to offer consistent returns?
    • From Needle and Thread to Virar’s Spotlight: DhaagaDhari’s Handmade Brand Wins Hearts at Virar Flea Market
    • Meeta Kotadia brings international recognition to India, winning the 2nd Runner-Up title along with two prestigious special awards at the global beauty pageant.

    Type above and press Enter to search. Press Esc to cancel.